Vestal Point Capital’s Palisade Bio PALI Stock Holding History

Vestal Point Capital’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.22M	Hold	2,500,000	–	–	0.12%	61
2026 Q1	$4.38M	Buy	+2,500,000	New	+$4.55M	0.12%	75

Other funds holding PALI

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vestal Point Capital's PALI Position: Q2 2026 in Review

Vestal Point Capital held its Palisade Bio (PALI) position steady in Q2 2026 at 2,500,000 shares worth $5.22M. The position accounts for 0.12% of the portfolio, ranked #61.

Vestal Point Capital first reported a position in PALI in Q1 2026 and has held it in 2 quarters since. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

Vestal Point Capital held 2,500,000 shares of Palisade Bio worth $5.22M as of Q2 2026.
Vestal Point Capital left its Palisade Bio share count unchanged in Q2 2026.
Palisade Bio made up 0.12% of Vestal Point Capital's portfolio in Q2 2026, its #61 holding.
Vestal Point Capital first reported a position in Palisade Bio in Q1 2026 and has held it in 2 quarters since.
124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.